Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1980 Sep;33(9):880–884. doi: 10.1136/jcp.33.9.880

Changes in the molecular size distribution and post-transfusion survival of hydroxyethyl starch 350/0.60 as influenced by a lower degree of hydroxyethylation: a study in normal man.

J M Mishler, C R Ricketts, E J Parkhouse
PMCID: PMC1146251  PMID: 6159372

Abstract

The need to provide a greater rate of colloid clearance from blood than is presently available with the long-acting dosage form of HES 450/0.70 prompted the clinical investigation of a new species of hydroxyethyl starch (HES) possessing a M-w of 350000 concomitant with a molar substitution of 0.60 (HES 350/0.60). The concentration of HES 350/0.60 in serum fell to half its peak value in 10.2 +/- 0.7 (SD) hour (in contrast to an IT50 of approximately 25 hours with HES 450/0.70). Levels of glucose in serum remained elevated in normal fasted subjects after dosing, suggesting that catabolism of the infused HES 350/0.60 was occurring. Hydrolysis of residual HES 350/0.60 was confirmed by Sepharose CL-4B gel filtration analysis of material obtained from serum, showing continual production of smaller molecules relative to the injected solution (in contrast to HES 450/0.70, in which intermediate polymer fragments are recovered). Recovered HES 350/0.60 material displayed a Kav ranging between 0.74 and 0.72 and possessed a Stokes radius (r = 45A) similar to that of dextran 40 (M-w 41000). HES 350/0.69 appears to offer the same advantages as the currently available long-acting HES 450/0.70 but is removed from blood approximately twice as rapidly. This more rapid hydrolysis of HEs 350/0.60 may be useful, for example, in avoiding cumulative build-up of colloid in the blood of normal donors undergoing consecutive leucapheresis procedures.

Full text

PDF
880

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARTURSON G., WALLENIUS G. THE INTRAVASCULAR PERSISTENCE OF DEXTRAN OF DIFFERENT MOLECULAR SIZES IN NORMAL HUMANS. Scand J Clin Lab Invest. 1964;16:76–80. doi: 10.3109/00365516409060485. [DOI] [PubMed] [Google Scholar]
  2. Benbunan M., Bussel A., Reviron J., Boiron M., Bernard J. Les transfusions de granulocytes normaux prélevés sur séparateur de cellules. Résultats techniques et cliniques. Nouv Rev Fr Hematol. 1973 Jul-Aug;13(4):469–485. [PubMed] [Google Scholar]
  3. Boon J. C., Jesch F., Ring J., Messmer K. Intravascular persistence of hydroxyethyl starch in man. Eur Surg Res. 1976;8(6):497–503. doi: 10.1159/000127896. [DOI] [PubMed] [Google Scholar]
  4. Farrow S. P., Hall M., Ricketts C. R. Changes in the molecular composition of circulating hydroxyethyl starch. Br J Pharmacol. 1970 Apr;38(4):725–730. doi: 10.1111/j.1476-5381.1970.tb09880.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Granath K. A., Kvist B. E. Molecular weight distribution analysis by gel chromatography on Sephadex. J Chromatogr. 1967 May;28(1):69–81. doi: 10.1016/s0021-9673(01)85930-6. [DOI] [PubMed] [Google Scholar]
  6. Lowenthal R. M., Park D. S., Goldman J. M. Toxicities of dextrans. Transfusion. 1976 Nov-Dec;16(6):648–649. doi: 10.1046/j.1537-2995.1976.16677060251.x. [DOI] [PubMed] [Google Scholar]
  7. Metcalf W., Papadopoulos A., Tufaro R., Barth A. A clinical physiologic study of hydroxyethyl starch. Surg Gynecol Obstet. 1970 Aug;131(2):255–267. [PubMed] [Google Scholar]
  8. Mishler J. M., 4th The plasma kinetics of hydroxyethyl starch 350/0.60: a potential new adjunct for centrifugal leucapheresis. Am J Hematol. 1979;7(4):341–347. doi: 10.1002/ajh.2830070406. [DOI] [PubMed] [Google Scholar]
  9. Mishler J. M., Borberg H., Emerson P. M., Gross R. Hydroxyethyl starch: an agent for hypovolemic shock treatment. J Surg Res. 1977 Oct;23(4):239–245. doi: 10.1016/0022-4804(77)90171-8. [DOI] [PubMed] [Google Scholar]
  10. Mishler J. M., Hadlock D. C., Fortuny I. E., Nicora R. W., McCullough J. J. Increased efficiency of leukocyte collection by the addition of hydroxyethyl starch to the continuous flow centrifuge. Blood. 1974 Oct;44(4):571–581. [PubMed] [Google Scholar]
  11. Mishler J. M., Higby D. J., Rhomberg W., Cohen E., Nicora R. W., Holland J. F. Hydroxyethyl starch and dexamethasone as an adjunct to leukocyte separation with the IBM blood cell separator. Transfusion. 1974 Jul-Aug;14(4):352–356. doi: 10.1111/j.1537-2995.1974.tb04544.x. [DOI] [PubMed] [Google Scholar]
  12. Mishler J. M., Ricketts C. R., Parkhouse E. J., Borberg H., Gross R. Catabolism of low-molecular-weight hydroxyethylated amylopectin in man. I. Changes in the circulating molecular composition. J Lab Clin Med. 1979 Dec;94(6):841–847. [PubMed] [Google Scholar]
  13. Mishler J. M., Ricketts C. R., Parkhouse E. J. Changes in the molecular composition of circulating hydroxyethyl starch following consecutive daily infusions in man. Br J Clin Pharmacol. 1979 May;7(5):505–509. doi: 10.1111/j.1365-2125.1979.tb00994.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Mishler J. M., Ricketts C. R., Parkhouse E. J. Post-transfusion survival of hydroxyethyl starch 450/0.70 in man: a long-term study. J Clin Pathol. 1980 Feb;33(2):155–159. doi: 10.1136/jcp.33.2.155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Rock G., Wise P. Plasma expansion during granulocyte procurement: cumulative effects of hydroxyethyl starch. Blood. 1979 Jun;53(6):1156–1163. [PubMed] [Google Scholar]
  16. SCHMIDT F. H. [Enzymatic determination of glucose and fructose simultaneously]. Klin Wochenschr. 1961 Dec 1;39:1244–1247. doi: 10.1007/BF01506150. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES